QNTM

Quantum BioPharma Ltd

• TipRanks·04/02 13:55

  Quantum BioPharma Cleared to Proceed With $700 Million Market Manipulation Lawsuit After Motion to Dismiss Largely Denied

• Benzinga·04/02 12:34

  Quantum BioPharma Announces U.S. District Court For The Southern District Of New York Rules Against CIBC World Markets, RBC Dominion Securities Joint Motion To Reject Quantum's Lawsuit

• Reuters·04/02 12:32

  QUANTUM BIOPHARMA: WINS COURT CHALLENGE IN $700 MLN CLAIM AS DEFENDANTS JOINT MOTION TO DISMISS LAWSUIT ALLEGING MARKET MANIPULATION BY CIBC & RBC

• Reuters·04/02 12:31

  Quantum BioPharma wins court fight as judge rejects bid to dismiss USD 700 million suit

• TipRanks·04/01 12:44

  Quantum BioPharma Files FDA IND for Phase 2 Trial of Lucid-MS in Multiple Sclerosis

• TipRanks·04/01 12:25

  Quantum BioPharma submits Lucid-21-302 new drug application to the FDA

• Benzinga·04/01 12:09

  Quantum BioPharma Submits IND Application To FDA For Lucid-21-302, Its New Drug Candidate For Treatment Of Multiple Sclerosis

• Reuters·04/01 12:04

  Quantum BioPharma submits FDA IND for Lucid-MS Phase 2 trial in multiple sclerosis

• Reuters·04/01 12:02

  QUANTUM BIOPHARMA LTD - PHASE 2 INTERIM DATA FOR LUCID-MS PROJECTED FOR Q4 2026

• TipRanks·03/30 13:07

  Quantum BioPharma Taps Allucent for Phase 2 Trial of Novel MS Drug Lucid-MS

• TipRanks·03/30 12:28

  Quantum BioPharma signs letter of intent with Allucent to conduct Lucid-MS trial

• Benzinga·03/30 12:05

  12 Health Care Stocks Moving In Monday's Pre-Market Session

• Benzinga·03/30 11:54

  Quantum BioPharma Enters Into Binding LOI With Allucent To Support Planned Phase 2 Clinical Trial Of Lucid-MS For Treatment Of Multiple Sclerosis

• Reuters·03/30 11:51

  Quantum BioPharma signs LOI with Allucent for Lucid-MS Phase 2 trial in multiple sclerosis

• Reuters·03/30 11:50

  QUANTUM BIOPHARMA SIGNS BINDING LETTER OF INTENT WITH ALLUCENT TO CONDUCT PHASE 2 CLINICAL TRIAL IN MULTIPLE SCLEROSIS